WO2023013301A1 - プロテオグリカンを含む軟骨成分混合物の製造方法 - Google Patents

プロテオグリカンを含む軟骨成分混合物の製造方法 Download PDF

Info

Publication number
WO2023013301A1
WO2023013301A1 PCT/JP2022/025701 JP2022025701W WO2023013301A1 WO 2023013301 A1 WO2023013301 A1 WO 2023013301A1 JP 2022025701 W JP2022025701 W JP 2022025701W WO 2023013301 A1 WO2023013301 A1 WO 2023013301A1
Authority
WO
WIPO (PCT)
Prior art keywords
cartilage
proteoglycan
mass
production method
component mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/025701
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
達治 高橋
俊昭 藤根
里沙 ワイズ
知也 岡本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichimaru Pharcos Co Ltd
Original Assignee
Ichimaru Pharcos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichimaru Pharcos Co Ltd filed Critical Ichimaru Pharcos Co Ltd
Priority to JP2022564511A priority Critical patent/JP7220941B1/ja
Priority to CN202280038478.6A priority patent/CN117460739A/zh
Priority to US18/577,697 priority patent/US20240317824A1/en
Priority to JP2022174079A priority patent/JP7846899B2/ja
Publication of WO2023013301A1 publication Critical patent/WO2023013301A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals

Definitions

  • Proteoglycan (hereinafter sometimes referred to as "PG") is a glycoprotein in which several to several tens of glycosaminoglycans such as chondroitin sulfate and keratan sulfate are covalently bound to one core protein. It is widely distributed in the body such as skin and cartilage as one of the PG in cartilage forms aggregates with collagen and hyaluronic acid, and a typical cartilage-type PG is called aggrecan.
  • Aggrecan has a large amount of glycosaminoglycan sugar chains bound to its core protein, and has a binding region for hyaluronic acid and link protein on its N-terminal side.
  • the molecular weight of proteoglycan in the cartilage component mixture containing proteoglycan obtained by this second embodiment is preferably 400,000 to 650,000.
  • the residue was put into 550 L of 99% ethanol again and stirred at 50° C. for 30 minutes.
  • the residue was put into 550 L of 99% ethanol again and washed with stirring at 50° C. for 30 minutes.
  • the pulverized material was collected by centrifugation, dried under reduced pressure at a heating temperature of 35° C. or lower, and the obtained dried material was pulverized with a pulverizer to obtain about 40 kg of pulverized material.
  • - PG yield (%) Value (%) calculated by "((content of proteoglycan in obtained freeze-dried product)/(weight of nasal cartilage 400 (g))) x 100".
  • PG molecular weight (x 10 4 ) proteoglycan molecular weight.
  • the description of "72" in Example 10 of Table 2 indicates a molecular weight of 720,000 (720,000).
  • Collagen content (%) Collagen content in the freeze-dried product.
  • the cells were cultured for 24 hours in an environment of 37° C. and 5% CO 2 .
  • the medium was replaced with a sample-containing medium (200 ⁇ l of DMEM medium containing 0.1% FBS).
  • a control group was prepared in which the cells were cultured only in a DMEM medium containing 0.1% FBS without the prescribed sample.
  • the cells were cultured for 72 hours in an environment of 37° C. and 5% CO 2 .
  • the cell growth effect of the added samples (Sample 1 to Sample 3 groups) was evaluated using CellTiter-GloTM Luminescent Cell Viability Assay (Promega). Statistical significance of the obtained test results was evaluated using Dunnett's test.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP2022/025701 2021-08-06 2022-06-28 プロテオグリカンを含む軟骨成分混合物の製造方法 Ceased WO2023013301A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022564511A JP7220941B1 (ja) 2021-08-06 2022-06-28 プロテオグリカンを含む軟骨成分混合物の製造方法
CN202280038478.6A CN117460739A (zh) 2021-08-06 2022-06-28 包含蛋白多糖的软骨成分混合物的制造方法
US18/577,697 US20240317824A1 (en) 2021-08-06 2022-06-28 Method for producing cartilage component mixture including proteoglycan
JP2022174079A JP7846899B2 (ja) 2021-08-06 2022-10-31 プロテオグリカンを含む軟骨成分混合物の製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021129997 2021-08-06
JP2021-129997 2021-08-06

Publications (1)

Publication Number Publication Date
WO2023013301A1 true WO2023013301A1 (ja) 2023-02-09

Family

ID=85154009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/025701 Ceased WO2023013301A1 (ja) 2021-08-06 2022-06-28 プロテオグリカンを含む軟骨成分混合物の製造方法

Country Status (4)

Country Link
US (1) US20240317824A1 (https=)
JP (2) JP7220941B1 (https=)
CN (1) CN117460739A (https=)
WO (1) WO2023013301A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919508A (zh) * 2024-01-25 2024-04-26 百瑞德（南京）生物科技有限公司 一种鼻软骨提取物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095795A (ja) * 1998-09-18 2000-04-04 Seikagaku Kogyo Co Ltd プロテオグリカンのコアタンパク質のポリペプチド及びそれをコードするｄｎａ
JP2012236776A (ja) * 2011-05-09 2012-12-06 Institute Glycosmo Co Ltd プロテオグリカンの製造方法
JP2020127397A (ja) * 2019-02-08 2020-08-27 一丸ファルコス株式会社 プロテオグリカンの製造方法
JP2020200288A (ja) * 2019-06-12 2020-12-17 国立大学法人東京農工大学 変形性関節症予防又は改善剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3731150B2 (ja) 2000-08-22 2006-01-05 株式会社角弘 軟骨型プロテオグリカンの精製方法
JP6317053B1 (ja) 2018-01-17 2018-04-25 一丸ファルコス株式会社 プロテオグリカンの製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095795A (ja) * 1998-09-18 2000-04-04 Seikagaku Kogyo Co Ltd プロテオグリカンのコアタンパク質のポリペプチド及びそれをコードするｄｎａ
JP2012236776A (ja) * 2011-05-09 2012-12-06 Institute Glycosmo Co Ltd プロテオグリカンの製造方法
JP2020127397A (ja) * 2019-02-08 2020-08-27 一丸ファルコス株式会社 プロテオグリカンの製造方法
JP2020200288A (ja) * 2019-06-12 2020-12-17 国立大学法人東京農工大学 変形性関節症予防又は改善剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919508A (zh) * 2024-01-25 2024-04-26 百瑞德（南京）生物科技有限公司 一种鼻软骨提取物的制备方法

Also Published As

Publication number Publication date
US20240317824A1 (en) 2024-09-26
JPWO2023013301A1 (https=) 2023-02-09
CN117460739A (zh) 2024-01-26
JP7220941B1 (ja) 2023-02-13
JP7846899B2 (ja) 2026-04-16
JP2023024427A (ja) 2023-02-16

Similar Documents

Publication Publication Date Title
EP3762050B1 (en) Nanocellulose-containing bioinks for 3d bioprinting, methods of making and using the same, and 3d biostructures obtained therefrom
Siqueira et al. Gelatin and galactomannan-based scaffolds: Characterization and potential for tissue engineering applications
CN110655568A (zh) 一种酸性酶解法提取胶原蛋白的方法
KR20180018055A (ko) 철갑상어 유래 유용물질을 포함하는 주름개선 화장료 조성물, 그 유용물질의 수득방법과 그 유용물질을 이용한 주름개선 화장품 제조방법
KR20170098951A (ko) 진주단백질 제조방법 및 이 제조방법에 의해 얻은 수용성 진주단백질과 산 용해성 진주단백질
Vachiraroj et al. A comparison of Thai silk fibroin-based and chitosan-based materials on in vitro biocompatibility for bone substitutes
JP7220941B1 (ja) プロテオグリカンを含む軟骨成分混合物の製造方法
JPWO2013073404A1 (ja) 米タンパク質組成物とその製造方法
CN113563458A (zh) 一种非变性ii型胶原蛋白的制备方法
Girón-Hernández et al. From cocoa waste to sustainable bioink: valorising pectin for circular economy-driven tissue engineering
CN103627768A (zh) 鱼皮胶原蛋白生物活性小肽及其制备方法
JP7295572B2 (ja) プロテオグリカンの製造方法
CN108785751B (zh) 鱼鳞胶原蛋白/海藻酸钠复合多孔骨组织工程支架及其制备方法与应用
Xu et al. A self-assembled dynamic extracellular matrix-like hydrogel system with multi-scale structures for cell bioengineering applications
Adibhosseini et al. Composite cryogel of gelatin/nanofibrillated cellulose/partially demineralized chitin with potential for bone tissue engineering
JP2026069717A (ja) プロテオグリカンを含む軟骨成分混合物の製造方法
CN104087640A (zh) 一种利于皮肤或粘膜吸收的鹿茸多肽系列提取方法
Li et al. Toxicity study of isolated polypeptide from wool hydrolysate
US20220089787A1 (en) Method for manufacturing proteoglycan-containing composition, and proteoglycan-containing composition
CN106890314B (zh) 珍珠提取物在制备抑制早衰素生成的药物、保健品和化妆品中的应用
DE102006026591A1 (de) Isoliertes naturidentisches Kollagen
WO2017109755A1 (en) Gellan gum-based hydrogels, methods and uses thereof
CN117752863A (zh) 一种脱细胞基质/脱蛋白骨粉复合生物墨水及其制备方法和应用
CN111235202A (zh) 一种鹿骨蛋白质提取物及其制备方法与应用
CN102429923B (zh) 一种马鹿鹿茸多肽及其治疗骨病的用途

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2022564511

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22852727

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280038478.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 18577697

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22852727

Country of ref document: EP

Kind code of ref document: A1